Effects of Low-Dose Olanzapine on Duloxetine-Related Nausea and Vomiting for the Treatment of Major Depressive Disorder

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JCP.0000000000000167PMID 24943388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of Chemotherapy-Induced Nausea and Vomiting

  2013cited by this paper
• Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol.

  2012cited by this paper
• [Prevention of nausea and vomiting in pain medication for digestive cancer].

  2012cited by this paper
• Preclinical discovery of duloxetine for the treatment of depression

  2012cited by this paper
• Management of Chemotherapy Induced Nausea and Vomiting

  2012cited by this paper
• Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.

  2012cited by this paper
• Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

  2011cited by this paper
• The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder

  2009cited by this paper
• Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

  2009cited by this paper
• Whole brain radiotherapy with radiosensitizer for brain metastases

  2009cited by this paper
• Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians.

  2008cited by this paper
• A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.

  2007cited by this paper
• Risk Factors for Postoperative Nausea and Vomiting

  2006cited by this paper
• Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses.

  2005cited by this paper
• Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.

  2004cited by this paper
• Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

  2004cited by this paper
• Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects

  2004cited by this paper
• Duloxetine in the long-term treatment of major depressive disorder.

  2003cited by this paper
• A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.

  2002cited by this paper
• Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

  2002cited by this paper
• Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

  2002cited by this paper
• Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.

  2001cited by this paper
• Olanzapine. Pharmacokinetic and pharmacodynamic profile.

  1999cited by this paper
• The role of 5-HT2C receptors in affective disorders.

  1998cited by this paper
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996cited by this paper
• Dopamine receptor pharmacology.

  1994cited by this paper
• Dopamine receptor pharmacology.

  1993cited by this paper
• A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.

  1983cited by this paper

• Drug-drug interaction of paroxetine on olanzapine and initial dosage optimization in patients with major depressive disorder based on population pharmacokinetics

  2025cites this paper
• Low-Dose Olanzapine in the Treatment of Adolescents with Anorexia Nervosa: An Observational Naturalistic Case–Control Study

  2022influential citation
• Effect of Preoperative Duloxetine on Opioid Consumption in Women Undergoing Abdominal Hysterectomy: A Randomized, Double-Blinded, Placebo-Controlled Trial

  2020cites this paper
• Duloxetine for the treatment acute postoperative pain in adult patients: A systematic review with meta-analysis.

  2020cites this paper
• Olanzapine Treatment for Refractory Nausea and Vomiting After Transarterial Embolization for Cerebral Arteriovenous Malformation.

  2020cites this paper
• Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China

  2018cites this paper
• Newest Drugs for Chronic Unexplained Nausea and Vomiting

  2016cites this paper
• Chapter 6 - Antipsychotic Drugs

  2015cites this paper
• Olanzapine in the Treatment of Refractory Nausea and Vomiting: A Case Report and Review of the Literature

  2015cites this paper